Original Articles
6 July 2016
Vol. 11 No. 2 (2017)
https://doi.org/10.4081/itjm.2016.715

Effects of the availability of new oral anticoagulants in patients with non-valvular atrial fibrillation in the real world: the NAIF study

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Atrial fibrillation, prevention of stroke, new oral anticoagulants, direct oral anticoagulants, adherence to guidelines.
1792
Views
919
Downloads
341
HTML

Authors

Francesco Ventrella
f.ventrella@tiscali.it
Department of Internal Medicine, G. Tatarella Hospital, Cerignola (FG), Italy.
Franco Mastroianni
Department of Geriatrics, F. Miulli Hospital, Acquaviva delle Fonti (BA), Italy.
Sergio Cappello
Department of Internal Medicine, G. Tatarella Hospital, Cerignola (FG), Italy.
Luigi Iamele
Department of Internal Medicine, G. Tatarella Hospital, Cerignola (FG), Italy.
Samantha Errico
Department of Geriatrics, F. Miulli Hospital, Acquaviva delle Fonti (BA), Italy.
Massimo Errico
Department of Geriatrics, F. Miulli Hospital, Acquaviva delle Fonti (BA), Italy.
Guidelines recommend anticoagulation to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). In the real world, this treatment is underused, probably for pharmacologic limitations of vitamin-K-antagonist (VKA). The new oral anticoagulants (NOAC) overcome many limitations of VKA. The aim of this study is to assess if, after introduction of NOAC, anticoagulated patients are increased. We performed an observational retrospective cohort study about patients with NVAF, hospitalized in Internal Medicine or Geriatrics for any cause in two years, before and after the marketing of NOAC. The results showed: 640 patients enrolled (289 in 2012, 351 in 2015), elderly population (83±7), males 42% females 58%, high morbidity, high thromboembolic (CHA2DS2VASc 5±1.6) and hemorrhagic (HASBLED 2.7±1.2) risks, with frequent chronic renal disease (51% stage ‰¥3) and contraindications to anticoagulants (21.6%). Therapy at discharge 2012 vs 2015: VKA 124/289 (43%) vs VKA or NOAC 187/351 (53%) (P<0.01); antiplatelet 114/289 (39%) vs 70/351 (20%) (P<0.0001). For the high comorbidity, frequent use of low-molecular-weight heparin: 42/289 (15%) in 2012 vs 77/351 (22%) in 2015. NOAC have increased the adherence to guidelines in prescribing oral anti-coagulants in patients with NVAF.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Effects of the availability of new oral anticoagulants in patients with non-valvular atrial fibrillation in the real world: the NAIF study. (2016). Italian Journal of Medicine, 11(2), 176-183. https://doi.org/10.4081/itjm.2016.715

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.